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Abstract Ideally, treatment of chronic hepatitis B in its early stage prior to irreversible liver damage
should be most effective in preventing adverse clinical outcome. However, currently available treatments
have low efficacy in achieving sustained response among patients in the early phase of chronic hepatitis B
infection when the immune response to hepatitis B virus is weak. This review will provide evidence why
a ‘wait and monitor’ approach is appropriate for chronic hepatitis B patients who are in the immune tol-
erant phase.
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INTRODUCTION
Remarkable progress has been made in the treatment of
chronic hepatitis B in the past decade. Treatment
options have expanded from a single approved treat-
ment that has to be administered parenterally, has many
unpleasant side-effects, is expensive, and has limited
efficacy and applicability to three approved treatments
including two orally administered antiviral compounds
which have very few side-effects. Nevertheless, current
treatments are far from satisfactory. Sustained off-
treatment response is achieved in a very small percent of
patients. Maintenance of on-treatment response
requires long-term therapy with increasing costs, and
risks of drug-resistance and adverse effects. Thus, deci-
sion to initiate treatment must carefully balance long-
term benefits against long-term costs and risks, as well
as patient preference, age, comorbid conditions and
severity of liver disease. The natural history of chronic
HBV infection can be depicted as consisting of four
phases: immune tolerant phase, immune clearance
phase (HBeAg positive chronic hepatitis), inactive car-
rier state, and reactivation (HBeAg negative chronic
hepatitis). Treatment guidelines recommend that
patients with HBeAg positive chronic hepatitis and
those with HBeAg negative chronic hepatitis be treated
because antiviral therapy can decrease hepatic necroin-
flammation and risk of progression of liver disease.1–4
Treatment is not recommended for inactive carriers
who have low or undetectable serum HBV DNA (< 103
copies/mL) and normal alanine aminotransferase
(ALT) levels. Current treatment will not bring about
further improvement and is unlikely to eradicate HBV,
clear hepatitis B surface antigen (HBsAg) or prevent
future reactivation. These carriers should be monitored
and treatment instituted if they should progress to
HBeAg negative chronic hepatitis. Much of the contro-
versy regarding hepatitis B treatment is focused on
patients in the first phase—immune tolerant phase.
WHAT IS THE IMMUNE TOLERANT 
PHASE?
The ‘immune tolerant’ phase of chronic HBV infection
is characterized by the presence of HBsAg, HBeAg,
high serum HBV DNA levels (107-1010 copies/mL),
persistently normal ALT levels, and minimal or no
hepatic inflammation and fibrosis if a liver biopsy is per-
formed.1 The classical patient in the ‘immune tolerant’
phase is a young (< 30 years) Asian patient with perin-
atally acquired HBV infection.
Evidence of immune tolerance was provided by stud-
ies of peripheral blood mononuclear cells in HBeAg-
positive Chinese children with normal ALT levels and
cord blood mononuclear cells from neonates of HBsAg
and HBeAg-positive carrier mothers showing lack of
proliferative response to HBcAg that was not reversed
by depleting CD8+ suppressor T cells.5 However, it
should be noted that tolerance is not permanent
because HBe/HBcAg-specific T cell proliferative
responses have been demonstrated to increase during
acute exacerbations of chronic hepatitis B and in
HBeAg-positive Chinese children with elevated ALT.5,6
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Longitudinal follow-up studies also showed that ele-
vated ALT and acute exacerbations of chronic
hepatitis B can be observed indicating that ‘immune
tolerance’ is a reversible state.7
WHAT ARE THE GOALS OF 
TREATMENT OF HEPATITIS B?
The primary goal of treatment of hepatitis B is to pre-
vent adverse clinical outcome: cirrhosis, liver failure and
HCC. The end-point of treatment of HBeAg-positive
patients is HBeAg to anti-HBe seroconversion with
associated suppression of serum HBV DNA to
<100 000 copies/mL and normalization of ALT.8 Sev-
eral long-term follow-up studies have demonstrated
that responders have improved clinical outcome. Intu-
itively, maximum benefit would be derived if treatment
can be initiated early and response achieved before
there is irreversible liver damage. Thus, hepatitis B
patients in the immune tolerant phase are ideal candi-
dates for treatment provided effective treatment is
available.
WHAT IS THE EFFICACY OF 
CURRENTLY APPROVED 
TREATMENTS?
Three treatments have been approved for chronic
hepatitis B: standard interferon alpha (IFNa), lamivu-
dine (Epivir), and adefovir dipivoxil (Hepsera).
IFNa
Clinical trials showed that compared to untreated con-
trols, a 4–6 month course of IFNa treatment results in
HBeAg clearance in an additional 24% (95% CI 8%-
30%) patients.9 The strongest predictor of response is
pretreatment ALT level.10,11 This explains why studies in
Asian patients that included patients with normal or
minimally elevated ALT levels reported very poor
response to IFNa therapy (Table 1).12–15 Subsequent
studies found that Asian patients with elevated ALT had
similar response rates as Caucasian patients15,16 indicat-
ing that host immune response at the time treatment is
initiated and not genetic factors led to the low response
rates in the early studies of Asian patients. These data
showed that IFNa has very limited efficacy in HBeAg
clearance—a surrogate marker for sustained viral sup-
pression, in hepatitis B patients who are in the immune
tolerant phase. However, Asian patients who have
entered the immune clearance phase (HBeAg positive,
elevated ALT levels) may benefit from IFNa therapy.
A phase II clinical trial of pegylated IFNa2a reported
that among patients with pretreatment ALT <2 times
upper limit of normal (ULN), a combined response
(HBeAg loss, serum HBV DNA <500 000 copies/mL
and ALT normalization) was achieved in six of
22 patients who received pegylated IFNa2a and in only
one of 9 who received standard IFNa2a suggesting that
pegylated IFN may have a role in hepatitis B patients
who are in the immune tolerant phase.17 However, the
number of patients was small and the exact number of
patients with normal pretreatment ALT was not speci-
fied. Given the costs and the associated side-effects, fur-
ther studies are needed to determine if pegylated IFNa
has any role in hepatitis B patients who are in the
immune tolerant phase.
Lamivudine
Clinical trials showed that a 1-year course of lamivudine
results in HBeAg seroconversion in 16–18% compared
to 4–6% of those who received placebo.18–20 As with
IFNa, pretreatment ALT is the strongest predictor of
response to lamivudine. This is true for adults as well as
children (Table 2)21 and Caucasians as well as Asians
(Table 3).22 While increasing rates of HBeAg serocon-
Table 1 Efficacy of IFNa therapy in controlled trials in HBeAg-positive Chinese patients
Author [ref] Treatment No. of patients Pretreatment ALT (¥ ULN) No. (%) patients lost HBeAg
Lai12,† IFNa 12 0.3 0
Control 12 0.3 0
Lai13,† IFNa ± Pred 60 0.3 5 (8)
Control 30 0.3 0
Lok14,† IFNa 54 1.5 9 (17)
Control 18 1.5 0
Lok15,† IFNa ± Pred 40 0.5 1 (2.5)
Control 20 0.5 0
IFNa ± Pred 39 3.5 14 (36)
Control 16 3.0 3 (19)
Liaw16,† IFNa ± Pred 76 6.0 27 (36)




version can be achieved by extending the duration of
lamivudine treatment, only 25% patients with normal
pretreatment ALT had HBeAg seroconversion after
5 years of lamivudine treatment.23 The low response
rate in relation to a 5-year rate of lamivudine-resistant
mutation of 69%23 cannot justify the use of long-term
lamivudine treatment for hepatitis B patients who are in
the immune tolerant phase. The importance of pretreat-
ment ALT in spontaneous and antiviral therapy related
HBeAg seroconversion was highlighted in an analysis of
805 adults who were treated with lamivudine, IFNa,
combination of IFNa and lamivudine, and placebo tab-
lets (Table 4).22
Adefovir dipivoxil
Phase III clinical trial of adefovir dipivoxil reported that
HBeAg seroconversion was observed in 12% and 6% of
patients after 1 year of adefovir dipivoxil 10 mg and pla-
cebo, respectively.24 A combined analysis of patients in
this trial and patients in a parallel trial conducted in
patients with HBeAg negative chronic hepatitis showed
that histologic response and HBV DNA suppression
was comparable in Asian and Caucasian patients.25
However, only 2% of patients in the trial of HBeAg-
positive hepatitis had normal pretreatment ALT levels.24
Thus, the efficacy of adefovir dipivoxil in hepatitis B
patients in the immune tolerant phase remains to be
determined.
WHY IS TREATMENT NOT 
RECOMMENDED FOR HEPATITIS B 
PATIENTS IN THE ‘IMMUNE 
TOLERANT’ PHASE?
The primary goal of hepatitis B treatment is to prevent
adverse clinical outcome. Accomplishment of this
goal necessitates that treatment can result in sustained
off-treatment virologic response, or maintenance of
response through continuous therapy. The latter
approach is practical only if the therapy is safe, afford-
able, and has a negligible risk of adverse effects with
long-term use. Such therapy is not yet available. Thus,
treatment is not recommended for hepatitis B patients
in the ‘immune tolerant’ phase because the long-term
benefits of currently available treatments do not out-
weigh the long-term costs; and risks of adverse effects
and drug resistance. Treatment is recommended when
‘immune tolerance’ is broken and these patients remain
HBeAg positive after ALT levels have been elevated for
longer than 6 months. Treatment at this stage is more
likely to be effective, and to benefit the patients by
shortening the period of active liver damage. In conclu-
sion, hepatitis B patients in the immune tolerant phase
are ideal candidates for treatment provided effective
treatment is available. Until then, the ‘immune tolerant’
patient should be monitored so treatment can be initi-
ated promptly when the time is ripe.
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